Atomoxetine use attention-deficit hyperactivity disorder and its treatment effects on brain resting-state functional connectivity.

Trial Profile

Atomoxetine use attention-deficit hyperactivity disorder and its treatment effects on brain resting-state functional connectivity.

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 23 Sep 2015

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Pharmacodynamics
  • Most Recent Events

    • 23 Sep 2015 New trial record
    • 16 Sep 2015 Results published in the International Journal of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top